Cor Vasa 2008, 50(7-8):299-303 | DOI: 10.33678/cor.2008.101
Combination therapy with epoprostenol and sildenafil in a female patient with severe pulmonary arterial hypertension
- Centrum pro plicní hypertenzi, II. interní klinika kardiologie a angiologie, Všeobecná fakultní nemocnice a 1. lékařská fakulta Univerzity Karlovy, Praha, Česká republika
The mainstay of treatment of pulmonary arterial hypertension is specific pharmacotherapy (with prostanoids, endothelin receptor antagonists, phosphodiesterase 5 inhibitors). Patients with severe pulmonary arterial hypertension have recently been shown to benefit from combination specific therapy as this therapy - by affecting several pathogenic mechanisms - is capable of stabilizing the clinical presentation of this serious condition necessarily deteriorating over time.
Keywords: Pulmonary arterial hypertension; Specific therapy; Combination specific therapy
Published: July 1, 2008 Show citation
| ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
Marešová J, Jansa P, Ambrož D, Poláček P, Jelínková L, Aschermann M, Linhart A. Combination therapy with epoprostenol and sildenafil in a female patient with severe pulmonary arterial hypertension. Cor Vasa. 2008;50(7-8):299-303. doi: 10.33678/cor.2008.101.
References
- Farber HW, Loscalzo J. Pulmonary arterial hypertension - mechanism of disease. N Engl J Med 2004;351: 1655-65.
Go to original source... 
Go to PubMed... - Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:56S-61S. Go to original source... Go to PubMed...
- Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57. Go to original source... Go to PubMed...